Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML

Abstract: This phase 1 study investigated the addition of gemtuzumab ozogamicin (GO) to intensive chemotherapy with cytarabine, daunorubicin, and midostaurin in 21 patients with newly diagnosed (ND) FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). Four dose levels of GO were e...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jayanshu Jain, Kelly Pugh, Shivani Handa, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Roland B. Walter, Rachel Cook, Jennifer Saultz, Ronan Swords, Junyang Li, George S. Laszlo, Nicole R. Grieselhuber, Alice S. Mims, Karilyn T. M. Larkin, Kieran Sahasrabudhe, James S. Blachly, Gregory K. Behbehani, Ann-Kathrin Eisfeld, Meixiao Long, Andrew Srisuwananukorn, Kristin L. Koenig, Uma Borate
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-02-01
Serie:	Blood Neoplasia
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2950328025001062
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!